SE9902550D0 - New crystalline forms - Google Patents

New crystalline forms

Info

Publication number
SE9902550D0
SE9902550D0 SE9902550A SE9902550A SE9902550D0 SE 9902550 D0 SE9902550 D0 SE 9902550D0 SE 9902550 A SE9902550 A SE 9902550A SE 9902550 A SE9902550 A SE 9902550A SE 9902550 D0 SE9902550 D0 SE 9902550D0
Authority
SE
Sweden
Prior art keywords
crystalline forms
new crystalline
melagatran
forms
crystalline
Prior art date
Application number
SE9902550A
Other languages
English (en)
Swedish (sv)
Inventor
Lena Hedstroem
Anita Lundblad
Sofia Naagaard
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Priority to SE9902550A priority Critical patent/SE9902550D0/xx
Publication of SE9902550D0 publication Critical patent/SE9902550D0/xx
Priority to TW089112623A priority patent/TWI250991B/zh
Priority to JP2001507862A priority patent/JP2003503508A/ja
Priority to CA002376944A priority patent/CA2376944A1/en
Priority to BR0012035-9A priority patent/BR0012035A/pt
Priority to AU60408/00A priority patent/AU765614B2/en
Priority to CNB008096902A priority patent/CN100537598C/zh
Priority to CZ20014722A priority patent/CZ20014722A3/cs
Priority to TR2001/03855T priority patent/TR200103855T2/xx
Priority to EP00946687A priority patent/EP1196431B1/en
Priority to NZ516187A priority patent/NZ516187A/en
Priority to ARP000103347A priority patent/AR035553A1/es
Priority to IL14697200A priority patent/IL146972A0/xx
Priority to MYPI20003011 priority patent/MY122760A/en
Priority to EEP200100646A priority patent/EE200100646A/xx
Priority to PT00946687T priority patent/PT1196431E/pt
Priority to PCT/SE2000/001398 priority patent/WO2001002426A1/en
Priority to US09/623,165 priority patent/US6479078B1/en
Priority to MXPA01013441A priority patent/MXPA01013441A/es
Priority to AT00946687T priority patent/ATE339438T1/de
Priority to RU2001134299/04A priority patent/RU2243973C2/ru
Priority to HU0202322A priority patent/HUP0202322A3/hu
Priority to KR1020017016964A priority patent/KR20020020765A/ko
Priority to DE60030723T priority patent/DE60030723T2/de
Priority to SK1883-2001A priority patent/SK18832001A3/sk
Priority to PL00352872A priority patent/PL352872A1/xx
Priority to SI200030904T priority patent/SI1196431T1/sl
Priority to ES00946687T priority patent/ES2270849T3/es
Priority to DK00946687T priority patent/DK1196431T3/da
Priority to ZA200109944A priority patent/ZA200109944B/en
Priority to IS6215A priority patent/IS6215A/is
Priority to NO20016419A priority patent/NO20016419L/no
Priority to HK02106968.3A priority patent/HK1045529B/zh
Priority to CY20061101785T priority patent/CY1107542T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Liquid Crystal Substances (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
SE9902550A 1999-07-02 1999-07-02 New crystalline forms SE9902550D0 (sv)

Priority Applications (34)

Application Number Priority Date Filing Date Title
SE9902550A SE9902550D0 (sv) 1999-07-02 1999-07-02 New crystalline forms
TW089112623A TWI250991B (en) 1999-07-02 2000-06-27 New crystalline forms of melagatran
DK00946687T DK1196431T3 (da) 1999-07-02 2000-06-30 En i det væsentlige krystallinsk form af melagatran
PCT/SE2000/001398 WO2001002426A1 (en) 1999-07-02 2000-06-30 A substantially crystalline form of melagatran
US09/623,165 US6479078B1 (en) 1999-07-02 2000-06-30 Substantially crystalline form of melagatran
BR0012035-9A BR0012035A (pt) 1999-07-02 2000-06-30 Melagatran, composto, processos para a produção de um composto, para a conversão de uma forma cristalina de um composto, para a interconversão de um composto anidrato, formulação farmacêutica, uso de um composto, e, método de tratamento de uma condição em que a inibição de trombina é requerida ou desejada
AU60408/00A AU765614B2 (en) 1999-07-02 2000-06-30 A substantially crystalline form of melagatran
CNB008096902A CN100537598C (zh) 1999-07-02 2000-06-30 美拉加川的实质性结晶形式
CZ20014722A CZ20014722A3 (cs) 1999-07-02 2000-06-30 V podstatě krystalická forma melagatranu
TR2001/03855T TR200103855T2 (tr) 1999-07-02 2000-06-30 Melagatranın büyük ölçüde kristalin bir formu.
EP00946687A EP1196431B1 (en) 1999-07-02 2000-06-30 A substantially crystalline form of melagatran
NZ516187A NZ516187A (en) 1999-07-02 2000-06-30 A substantially crystalline form of melagatran
ARP000103347A AR035553A1 (es) 1999-07-02 2000-06-30 Formas cristalinas de melagatran, proceso para su produccion, formulacion farmaceutica, y uso de este compuesto en la elaboracion de medicamentos.
IL14697200A IL146972A0 (en) 1999-07-02 2000-06-30 A substantially crystalline form of melagatran
MYPI20003011 MY122760A (en) 1999-07-02 2000-06-30 Substantially crystalline form of melagatran
EEP200100646A EE200100646A (et) 1999-07-02 2000-06-30 Melagatraani peaaegu kristalne vorm
PT00946687T PT1196431E (pt) 1999-07-02 2000-06-30 Forma fundamentalmente cristalina de melagatrano
JP2001507862A JP2003503508A (ja) 1999-07-02 2000-06-30 メラガトランの実質的結晶形
CA002376944A CA2376944A1 (en) 1999-07-02 2000-06-30 A substantially crystalline form of melagatran
MXPA01013441A MXPA01013441A (es) 1999-07-02 2000-06-30 Forma substancialmente cristalina de melagatran.
AT00946687T ATE339438T1 (de) 1999-07-02 2000-06-30 Substanziell kristalline form von melagatran
RU2001134299/04A RU2243973C2 (ru) 1999-07-02 2000-06-30 По существу, кристаллическая форма мелагатрана
HU0202322A HUP0202322A3 (en) 1999-07-02 2000-06-30 A substantially crystalline form of melagatran, process for obtaining it, pharmaceutical composition containing thereof and its use
KR1020017016964A KR20020020765A (ko) 1999-07-02 2000-06-30 실질적인 결정 형태의 멜라가트란
DE60030723T DE60030723T2 (de) 1999-07-02 2000-06-30 Substanziell kristalline form von melagatran
SK1883-2001A SK18832001A3 (sk) 1999-07-02 2000-06-30 Praktická kryštalická forma melagatranu
PL00352872A PL352872A1 (en) 1999-07-02 2000-06-30 A substantially crystalline form of melagatran
SI200030904T SI1196431T1 (sl) 1999-07-02 2000-06-30 V bistvu kristalna oblika melagatrana
ES00946687T ES2270849T3 (es) 1999-07-02 2000-06-30 Forma sustancialamente cristalina de melagatran.
ZA200109944A ZA200109944B (en) 1999-07-02 2001-12-03 A substantially crystalline form of melagatran.
IS6215A IS6215A (is) 1999-07-02 2001-12-27 Að mestu leyti kristallað form af melagatrani
NO20016419A NO20016419L (no) 1999-07-02 2001-12-28 Melagatran i vesentlig krystallinsk form
HK02106968.3A HK1045529B (zh) 1999-07-02 2002-09-24 基本上為結晶形式的美拉加群
CY20061101785T CY1107542T1 (el) 1999-07-02 2006-12-12 Μiα ουσιαστικa κρυσταλλικh μορφh μελαγατρaνης

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9902550A SE9902550D0 (sv) 1999-07-02 1999-07-02 New crystalline forms

Publications (1)

Publication Number Publication Date
SE9902550D0 true SE9902550D0 (sv) 1999-07-02

Family

ID=20416364

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9902550A SE9902550D0 (sv) 1999-07-02 1999-07-02 New crystalline forms

Country Status (33)

Country Link
US (1) US6479078B1 (xx)
EP (1) EP1196431B1 (xx)
JP (1) JP2003503508A (xx)
KR (1) KR20020020765A (xx)
CN (1) CN100537598C (xx)
AR (1) AR035553A1 (xx)
AT (1) ATE339438T1 (xx)
AU (1) AU765614B2 (xx)
BR (1) BR0012035A (xx)
CA (1) CA2376944A1 (xx)
CY (1) CY1107542T1 (xx)
CZ (1) CZ20014722A3 (xx)
DE (1) DE60030723T2 (xx)
DK (1) DK1196431T3 (xx)
EE (1) EE200100646A (xx)
ES (1) ES2270849T3 (xx)
HK (1) HK1045529B (xx)
HU (1) HUP0202322A3 (xx)
IL (1) IL146972A0 (xx)
IS (1) IS6215A (xx)
MX (1) MXPA01013441A (xx)
MY (1) MY122760A (xx)
NO (1) NO20016419L (xx)
NZ (1) NZ516187A (xx)
PL (1) PL352872A1 (xx)
PT (1) PT1196431E (xx)
RU (1) RU2243973C2 (xx)
SE (1) SE9902550D0 (xx)
SK (1) SK18832001A3 (xx)
TR (1) TR200103855T2 (xx)
TW (1) TWI250991B (xx)
WO (1) WO2001002426A1 (xx)
ZA (1) ZA200109944B (xx)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6976012B1 (en) 2000-01-24 2005-12-13 Sony Corporation Method and apparatus of using a neural network to train a neural network
AR035216A1 (es) * 2000-12-01 2004-05-05 Astrazeneca Ab Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios
US7129233B2 (en) * 2000-12-01 2006-10-31 Astrazeneca Ab Mandelic acid derivatives and their use as thrombin inhibitors
AR034517A1 (es) * 2001-06-21 2004-02-25 Astrazeneca Ab Formulacion farmaceutica
SE0201659D0 (sv) * 2002-05-31 2002-05-31 Astrazeneca Ab Modified release pharmaceutical formulation
SE0201661D0 (sv) 2002-05-31 2002-05-31 Astrazeneca Ab New salts
US7781424B2 (en) * 2003-05-27 2010-08-24 Astrazeneca Ab Modified release pharmaceutical formulation
JP4748449B2 (ja) * 2003-11-27 2011-08-17 味の素株式会社 フェニルアラニン誘導体の結晶及びその製造方法
US20050209211A1 (en) * 2004-03-16 2005-09-22 Devalina Law Trihemihydrate, anhydrate and novel hydrate forms of Cefdinir
US7524354B2 (en) * 2005-07-07 2009-04-28 Research Foundation Of State University Of New York Controlled synthesis of highly monodispersed gold nanoparticles
TW200827336A (en) * 2006-12-06 2008-07-01 Astrazeneca Ab New crystalline forms
US20090061000A1 (en) * 2007-08-31 2009-03-05 Astrazeneca Ab Pharmaceutical formulation use 030

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0687881A (ja) * 1992-09-07 1994-03-29 Asahi Chem Ind Co Ltd ロキタマイシン・一水和物結晶、及びその製造法
JP3077925B2 (ja) * 1992-12-15 2000-08-21 ヤマサ醤油株式会社 ２’−デオキシ−２’−メチリデンシチジン無水物結晶およびその製造法
SE9301916D0 (sv) 1993-06-03 1993-06-03 Ab Astra New peptides derivatives
SE9404196D0 (sv) * 1994-12-02 1994-12-02 Astra Ab New antithrombotic formulation
JP3182685B2 (ja) * 1995-09-01 2001-07-03 北陸製薬株式会社 水和物結晶及びその製造方法
JP2914324B2 (ja) * 1995-10-23 1999-06-28 味の素株式会社 ピペリジン誘導体の結晶並びにその製造中間体及び製造方法
TWI238827B (en) * 1995-12-21 2005-09-01 Astrazeneca Ab Prodrugs of thrombin inhibitors
SE9603724D0 (sv) * 1996-10-11 1996-10-11 Astra Ab New pharmaceutical parenteral formulation of a thrombin inhibitor
SE9802974D0 (sv) 1998-09-03 1998-09-03 Astra Ab New crystalline forms
FR2793418B1 (fr) * 1999-05-11 2001-07-27 Synthelabo Formulations galeniques d'agents antithrombotiques pour administration sous-cutanee

Also Published As

Publication number Publication date
KR20020020765A (ko) 2002-03-15
EP1196431B1 (en) 2006-09-13
CN100537598C (zh) 2009-09-09
HK1045529B (zh) 2007-02-23
US6479078B1 (en) 2002-11-12
HUP0202322A2 (en) 2002-10-28
BR0012035A (pt) 2002-03-19
WO2001002426A1 (en) 2001-01-11
EP1196431A1 (en) 2002-04-17
CY1107542T1 (el) 2013-03-13
JP2003503508A (ja) 2003-01-28
CZ20014722A3 (cs) 2002-05-15
CN1359389A (zh) 2002-07-17
AU6040800A (en) 2001-01-22
ZA200109944B (en) 2003-03-03
DE60030723T2 (de) 2007-11-08
TR200103855T2 (tr) 2002-04-22
IL146972A0 (en) 2002-08-14
PT1196431E (pt) 2007-01-31
MY122760A (en) 2006-05-31
TWI250991B (en) 2006-03-11
MXPA01013441A (es) 2002-07-02
DE60030723D1 (de) 2006-10-26
IS6215A (is) 2001-12-27
NO20016419L (no) 2002-03-01
CA2376944A1 (en) 2001-01-11
AR035553A1 (es) 2004-06-16
ES2270849T3 (es) 2007-04-16
PL352872A1 (en) 2003-09-08
HK1045529A1 (en) 2002-11-29
AU765614B2 (en) 2003-09-25
ATE339438T1 (de) 2006-10-15
NO20016419D0 (no) 2001-12-28
SK18832001A3 (sk) 2002-10-08
RU2243973C2 (ru) 2005-01-10
EE200100646A (et) 2003-02-17
HUP0202322A3 (en) 2003-04-28
DK1196431T3 (da) 2006-12-11
NZ516187A (en) 2004-09-24

Similar Documents

Publication Publication Date Title
AP1520A (en) Crystalline forms of EtO2C-CH2-(R)Cgl-Aze-Pab-OH
PT1193270E (pt) Pirrolobenzodiazepinas
CY1107542T1 (el) Μiα ουσιαστικa κρυσταλλικh μορφh μελαγατρaνης
IL154292A0 (en) Imidazolo-5-yl-2-anilino-pyrimidines as agents for the inhibition of the cell profiliferation
AU2001294197A1 (en) Aliphatic nitrogenous five-membered ring compounds
AU2002224927A1 (en) Use of substituted imidazoazines, novel imidazoazines, methods for the production thereof, and agents containing these compounds
EA200200510A1 (ru) 4-карбоксиамино-2-этил-1,2,3,4-тетрагидрохинолин в кристаллической форме как ингибитор сетр
IT1312115B1 (it) Composti amorfi e relative composizioni farmaceutiche
MY133969A (en) Indoloquinazolinones
HK1045990A1 (en) Novel derivatives and analogues of galanthamin.
TR200201128T2 (tr) PDE4 inhibitörleri olarak tetrahidrotiyopiranfitalazinon türevleri.
SE9903290D0 (sv) Novel compounds
MY128164A (en) Compounds
WO2002028855A3 (en) Amorphous form of cell cycle inhibitor
AU2001293207A1 (en) Nitrogenous heterocyclic compounds
MXPA06000372A (es) Compuestos de silicio y su uso.
AU1039801A (en) Compounds and their use as cysteine protease inhibitors
IS6093A (is) Notkun á madúraþalazín afleiðum sem lötum fyrir for-bólgu frumuboða
AU2002331362A1 (en) New alkynylated quinazolin compounds as mmp-13 inhibitors
TH60760A (th) รูปแบบผลึกแบบใหม่
AU2001248382A1 (en) Novel heterocyclic compounds with anti-inflammatory activity
AUPQ750100A0 (en) N-containing heterocyclic compounds
AUPR195500A0 (en) N-containing heterocyclic compounds
RS20050181A (xx) Novi benzonaftiridini
AUPQ961500A0 (en) N-containing heterocyclic compounds and their use